登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JAMA，5月27日，Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-05-28

  • Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

    Daniel A. Goldstein, MD1,2; Mark J. Ratain, MD3; Leonard B. Saltz, MD4

    Author Affiliations Article Information

    JAMA Oncol. Published online May 27, 2020. doi:10.1001/jamaoncol.2020.2493

    The coronavirus disease 2019 (COVID-19) pandemic has shocked the world and caused a period of both economic and medical catastrophe. Two major challenges face the world of medical oncology. Oncologists need to reconsider all of their clinical practices to decrease the risk of exposure of their patients to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Oncologists also need to consider that the world has changed considerably in economic terms. Now, more than ever, we need to assess whether our recommended therapies will cause financial hardship, on both an individual and a societal level. In this article we propose a solution related to the dosing of pembrolizumab that will maintain therapeutic outcomes, decrease detrimental financial effects of treatment, and decrease exposure risk to SARS-CoV-2.

  • 原文来源：https://jamanetwork.com/journals/jamaoncology/fullarticle/2766704
26浏览量
原文链接
相关报告

  • 《JAMA，5月6日，Estimated Demand for US Hospital Inpatient and Intensive Care Unit Beds for Patients With COVID-19 Based on Comparisons With Wuhan and Guangzhou, China》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-07
    • Estimated Demand for US Hospital Inpatient and Intensive Care Unit Beds for Patients With COVID-19 Based on Comparisons With Wuhan and Guangzhou, China Ruoran Li, MPhil1; Caitlin Rivers, PhD2; Qi Tan, MD, PhD3,4; et alMegan B. Murray, DPH, MD3; Eric Toner, MD2; Marc Lipsitch, DPhil1 Author Affiliations Article Information JAMA Netw Open. 2020;3(5):e208297. doi:10.1001/jamanetworkopen.2020.8297 Abstract Importance Sustained spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has happened in major US cities. Capacity needs in cities in China could inform the planning of local health care resources. Objectives To describe and compare the intensive care unit (ICU) and inpatient bed needs for patients with coronavirus disease 2019 (COVID-19) in 2 cities in China to estimate the peak ICU bed needs in US cities if an outbreak equivalent to that in Wuhan occurs. Design, Setting, and Participants This comparative effectiveness study analyzed the confirmed cases of COVID-19 in Wuhan and Guangzhou, China, from January 10 to February 29, 2020. Exposures Timing of disease control measures relative to timing of SARS-CoV-2 community spread. Main Outcomes and Measures Number of critical and severe patient–days and peak number of patients with critical and severe illness during the study period. Results In Wuhan, strict disease control measures were implemented 6 weeks after sustained local transmission of SARS-CoV-2. Between January 10 and February 29, 2020, patients with COVID-19 accounted for a median (interquartile range) of 429 (25-1143) patients in the ICU and 1521 (111-7202) inpatients with serious illness each day. During the epidemic peak, 19?425 patients (24.5 per 10?000 adults) were hospitalized, 9689 (12.2 per 10?000 adults) were considered in serious condition, and 2087 (2.6 per 10?000 adults) needed critical care per day. In Guangzhou, strict disease control measures were implemented within 1 week of case importation. Between January 24 and February 29, COVID-19 accounted for a median (interquartile range) of 9 (7-12) patients in the ICU and 17 (15-26) inpatients with serious illness each day. During the epidemic peak, 15 patients were in critical condition and 38 were classified as having serious illness. The projected number of prevalent critically ill patients at the peak of a Wuhan-like outbreak in US cities was estimated to range from 2.2 to 4.4 per 10?000 adults, depending on differences in age distribution and comorbidity (ie, hypertension) prevalence.
    133浏览量
    原文链接

  • 《Science，5月5日，Rapid implementation of mobile technology for real-time epidemiology of COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-06
    • Rapid implementation of mobile technology for real-time epidemiology of COVID-19 David A. Drew1,*, Long H. Nguyen1,*, Claire J. Steves2,3, Cristina Menni2, Maxim Freydin2, Thomas Varsavsky4, Carole H. Sudre4, M. Jorge Cardoso4, Sebastien Ourselin4, Jonathan Wolf5, Tim D. Spector2,5,†, Andrew T. Chan1,6,†,‡, COPE Consortium§ See all authors and affiliations Science 05 May 2020: eabc0473 DOI: 10.1126/science.abc0473 Abstract The rapid pace of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (COVID-19) presents challenges to the robust collection of population-scale data to address this global health crisis. We established the COronavirus Pandemic Epidemiology (COPE) consortium to bring together scientists with expertise in big data research and epidemiology to develop a COVID-19 Symptom Tracker mobile application that we launched in the UK on March 24, 2020 and the US on March 29, 2020 garnering more than 2.8 million users as of May 2, 2020. This mobile application offers data on risk factors, herald symptoms, clinical outcomes, and geographical hot spots. This initiative offers critical proof-of-concept for the repurposing of existing approaches to enable rapidly scalable epidemiologic data collection and analysis which is critical for a data-driven response to this public health challenge.
    37浏览量
    原文链接